 | This is not a Wikipedia article: It is an individual user's work-in-progress page, and may be incomplete and/or unreliable. For guidance on developing this draft, see Wikipedia:So you made a userspace draft. Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | 2009 |
| Founder | George Church Yemi Adesokan, CEO |
| Headquarters | , |
| Website | http://www.pathogenica.com/ |
Pathogenica is a biotechnology company founded to commercialize applications of pathogen sequencing. The company applies next generation DNA sequencing technology to meet clinical demand for rapid multiplex identification of pathogens, drug resistance genes, and toxins in patient samples. Pathogenica’s test kits are able to identify the presence of many pathogen variants within a complex sample by reading their nucleic acid sequence, allowing for physicians to screen for multiple diseases with accurate results and a rapid turnaround.
The company was founded in 2009 in Cambridge, Massachusetts, by Yemi Adesokan, a research fellow at Harvard Medical School, and Professor of Genetics, George Church, who initiated the Personal Genome Project. In addition to Church, the firm's scientific advisory board includes Ron Davis of the University of California, San Diego, W. Ian Lipkin of Columbia University, Kun Zhang of the University of California, San Diego, and Andrew Onderdonk of Harvard Medical School.
In 2011, Pathogenica CEO Yemi Adesokan was recognized by Technology Review magazine in the TR35, an annual listing of the world's top innovators under the age of 35, spanning energy, medicine, computing, communications, nanotechnology, and other emerging fields.
External links
edit
 | This United States corporation or company article is a stub. You can help Wikipedia by expanding it. |